Business Wire

IL-PRICEFX

16.12.2020 15:32:08 CET | Business Wire | Press release

Share
Pricefx Introduces Velo, The Industry’s First Strategic Large Deal Negotiation Solution

Pricefx , the global leader in cloud-native pricing software, today launched Velo, a unique offering for companies to maximize value on large deal negotiations. Designed to manage the largest transactional relationships in each business, Velo is the industry’s first solution specifically focused on helping sellers to prepare for, and win, profit-maximizing outcomes on large contract negotiations, bids, proposals and sourcing events. Combining a proven deal negotiation methodology with innovative technology for value estimation and leverage optimization, Velo now gives businesses the analytical insights, structured process and workflow automation to negotiate highly customized deals with confidence.

For many large B2B companies, the top 5-10% of their customers make up more than 50% of revenue. The agreements with those customers are essential to the company’s survival. With changes in demand, both buyers and sellers seek to optimize their largest positions as contracts and commitments naturally expire or get adjusted. Buyers often use powerful procurement platforms to optimize their position. With Velo, companies can now equip themselves with an equally powerful package of technology and strategy to maximize value, optimize leverage and negotiate to win.

“Companies have traditionally relied on spreadsheets and manual processes, without collaborative tools, thus leaving potential negotiation power unknown,” said Marcin Cichon, CEO and co-founder at Pricefx. “We are giving businesses a powerful, new way to manage large, complex deals, leveling the playing field in negotiations, and improving outcomes. Tribal wisdom and outdated CPQ technology are no match for the capabilities of Velo.”

“Procurement organizations continue to attack the profit and value positions of their largest suppliers,” said Brian Sharp, Chief Revenue Officer for Profit Velocity. “Category-by-category, sellers face a withering storm of sourcing event approaches with software and services geared toward depleting supplier profits and value. Velo is the first solution to re-balance the playing field so that suppliers can capture their fair share of the value they create for their largest customers.”

Pairing Pricefx ValueEstimator and LargeDealOptimizer modules with the proven methodology from partner Profit Velocity, Velo is a one-of-a-kind strategic software solution to maximize profitability and leverage in large deals. It pairs this software with a proven process-centered methodology, leveraging leading-edge scenario-based negotiation playbooks and a team of negotiation experts who have managed over 400 large complex deals with cumulative recurring revenues exceeding $8 Billion/year across a multitude of industry verticals.

LargeDealOptimizer facilitates the planning of large, complex deals with guidance and contextual information to support the negotiation of monolithic deals in one, central location. It manages deal teams through the workflow of establishing opening positions, anticipating buyer objections and counter-proposals, while aligning the team with their leadership’s objectives and governance. Efficiently streamlining, organizing, and approving complex customer transactions within the Pricefx platform, LargeDealOptimizer enables organizations to get the most value and profit from the customers that generate much of their revenue.

ValueEstimator enables companies to assess their differential competitive value based on the actual customer-based decision drivers. It establishes value-based pricing while enabling that value to be communicated when a price is set for a customer quote or proposal.

Velo provides a proven, immersive and agile service led by world-class negotiation experts, assuring business leaders and P&L owners that each deal team is ready to negotiate-to-win. While every large deal is customized by their very nature, the Velo solution provides a repeatable process-centered approach which fully integrates the new software tools. Early customer reviews of Velo say that Pricefx is offering “a unique new capability that connects its powerful price optimization engine to customer value data. We've waited a long time for this – a huge breakthrough for pricing leaders.”

Velo is easy-to-deploy and can be delivered one deal at-a-time or through a subscription-based approach to support the highest stakes deals. Historically businesses have consistently grown the profitability of their large customer transactions by an average of 440 basis points per deal by leveraging the Velo software and methodology.

Availability
Velo is available now and interested parties can learn more at www.hellovelo.com .

About Profit Velocity Solutions LLC
A San Francisco-based data analytics software company, Profit Velocity has pioneered the use of time-based profit data analytics that enable the management teams of large manufacturers to fine-tune their mix of customers and products and unlock significant investor gains. With its unique profit data visualizations and instant what-if planning, Profit Velocity’s profit information platform turns readily available data into potent new insights that allow decision-makers to isolate and capture gains previously buried in an ocean of corporate data. Profit Velocity has served manufacturers, large and small, across North America, Asia, and Europe. For more information, please visit www.profitvelocity.com .

About Pricefx
Established in 2011 in Germany, Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, flexible to configure and customize, and friendly to learn and use. Pricefx delivers a complete price optimization and management platform based on native cloud architecture, providing industry leading time to value and total cost of ownership advantages to customers. Their innovative solution works for both B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. Today, Pricefx delivers Passion for Pricing to more than 100 customers in more than 37 countries worldwide. For more information, please visit www.pricefx.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye